Cargando…

Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis

SIMPLE SUMMARY: Although cisplatin is very effective as a treatment strategy in triple-negative breast cancer (TNBC), it has unwarranted outcomes owing to recurrence, chemoresistance and neurotoxicity. In the current studies we determined a novel therapeutic option that enhances the efficacy of cisp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Emma, Pei, Guangsheng, Kim, Sang T., German, Alexis, Robinson, Prema
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345440/ https://www.ncbi.nlm.nih.gov/pubmed/34359773 http://dx.doi.org/10.3390/cancers13153871

Ejemplares similares

Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
por: Rodriguez, Emma, et al.
Publicado: (2021)

Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity
por: Legi, Ashiq, et al.
Publicado: (2021)

Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis
por: Robinson, Prema, et al.
Publicado: (2015)

Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance
por: Robinson, Prema, et al.
Publicado: (2016)

In vitro antagonism between cisplatin and vinca alkaloids.
por: Lee, K., et al.
Publicado: (1989)

Isoliquiritin Ameliorates Cisplatin-Induced Renal Proximal Tubular Cell Injury by Antagonizing Apoptosis, Oxidative Stress and Inflammation
por: Pei, Zhiyin, et al.
Publicado: (2022)

DEC2 expression antagonizes cisplatin-induced apoptosis in human esophageal squamous cell carcinoma
por: Sato, Hidenobu, et al.
Publicado: (2017)

Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model
por: Klein, Reuben, et al.
Publicado: (2007)

Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells
por: Chen, Lian, et al.
Publicado: (2016)

Protective effect of bioactive compounds from Echinophora cinerea against cisplatin-induced oxidative stress and apoptosis in the PC12 cell line
por: Shokoohinia, Yald, et al.
Publicado: (2017)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatin–GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin
por: Vascellari, Sarah, et al.
Publicado: (2019)

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
por: Telli, Melinda L., et al.
Publicado: (2022)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Synergy, Additivity, and Antagonism between Cisplatin and Selected Coumarins in Human Melanoma Cells
por: Wróblewska-Łuczka, Paula, et al.
Publicado: (2021)

Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells
por: Badea, Madalina Andreea, et al.
Publicado: (2018)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
por: Abu Bakar, Nur Fitriyani Afiqah Binti, et al.
Publicado: (2023)

Inducible HSP70 antagonizes cisplatin-induced cell apoptosis through inhibition of the MAPK signaling pathway in HGC-27 cells
por: Sheng, Lili, et al.
Publicado: (2018)

Bismuth Porphyrin Antagonizes Cisplatin-Induced Nephrotoxicity via Unexpected Metallothionein-Independent Mechanisms
por: Wang, Runming, et al.
Publicado: (2020)

Kinetic Analysis of Combination Effect of Navelbine (KW‐2307) with Cisplatin against Human Lung Adenocarcinoma PC‐12 Cells in Culture
por: Gomi, Katsushige, et al.
Publicado: (1992)

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells
por: Zhang, Yang, et al.
Publicado: (2018)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity
por: Heijink, Anne Margriet, et al.
Publicado: (2019)

Quantitative proteomic analysis of enhanced cellular effects of electrochemotherapy with Cisplatin in triple-negative breast cancer cells
por: Mittal, Lakshya, et al.
Publicado: (2019)

Urtica dioica Leaf Infusion Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Cisplatin Treatment
por: Nafeh, Guy, et al.
Publicado: (2023)

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment
por: Tanida, Satoshi, et al.
Publicado: (2012)

Independent transcriptional reprogramming and apoptosis induction by cisplatin
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

The role of apoptosis in cisplatin-induced ototoxicity in rats
por: De Freitas, Marcos Rabelo, et al.
Publicado: (2015)

Apoptosis Induction with Combined Use of Cisplatin and Fisetin in Cisplatin-Resistant Ovarian Cancer Cells (A2780)
por: Jafarzadeh, Samira, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8qgvc61hfpq0856sjrnpns74ri